A phase II evaluation of AMG 102 (rilotumumab) in the treatment of persistent or recurrent epithelial ovarian, fallopian tube or primary peritoneal carcinoma: a Gynecologic Oncology Group study.
about
Cancer-related and treatment-related fatigue.Anti-vascular therapies in ovarian cancer: moving beyond anti-VEGF approaches.The expression of aldehyde dehydrogenase 1 (ALDH1) in ovarian carcinomas and its clinicopathological associations: a retrospective studyExamination of the Fractalkine and Fractalkine Receptor Expression in Fallopian Adenocarcinoma Reveals Differences When Compared to Ovarian Carcinoma.Incomplete target neutralization by the anti-cancer antibody rilotumumab.INC280, an orally available small molecule inhibitor of c-MET, reduces migration and adhesion in ovarian cancer cell modelsDiagnostic Value of Serum Angiogenesis Markers in Ovarian Cancer Using Multiplex ImmunoassayImmune therapies for malignant mesothelioma.Targeting the oncogenic Met receptor by antibodies and gene therapy.cMET in triple-negative breast cancer: is it a therapeutic target for this subset of breast cancer patients?Potential role of rilotumumab in the treatment of gastric cancer.Pharmacokinetics and pharmacodynamics of rilotumumab: a decade of experience in preclinical and clinical cancer research.Promise and challenges on the horizon of MET-targeted cancer therapeuticsThe Therapeutic Potential of Targeting the HGF/cMET Axis in Ovarian Cancer.Targeting the tumor-promoting microenvironment in MET-amplified NSCLC cells with a novel inhibitor of pro-HGF activation.Clinical trials in gynecologic oncology: Past, present, and future.Recent Progress and Advances in HGF/MET-Targeted Therapeutic Agents for Cancer Treatment.HGF/c-MET Axis in Tumor Microenvironment and Metastasis Formation.
P2860
Q35164501-D96679AE-0B21-413F-AB43-F05F01E6B1FBQ35205410-A9B1D5D8-57BB-4263-9070-7852716279A3Q35684532-1DE7183A-9DAA-4322-A3D9-7B6ABDB2C7A8Q36409618-C8B020A3-5142-4E7E-B354-6516FAB7DA1AQ37138513-D48D5502-8AC3-44EA-AB4D-0000FE39DA51Q37502372-EC36ADAC-C3A2-4AD9-9644-427D7D625656Q37631567-09E9FF43-9A6D-4509-BF2C-6E38E35E5498Q38212149-9BFCEB20-60C9-4EF4-8D19-0E703CA3F45DQ38216590-B6A5452E-71F3-40B0-AB5D-3DA8654BDAD9Q38236096-5E510DA9-DA57-407C-9BA3-409C554FB408Q38294088-EDFE1C19-E30A-4ACE-82F5-1F7760D72641Q38442573-C8E42EB7-6268-4E44-898E-76A18200C898Q38502350-85DF1382-6310-4931-BDC4-5343182F062BQ38824065-4ABD7E67-BAD4-4E0D-A2D4-301FAD7F80E7Q41825773-A50C51A1-9DB4-486A-AFE5-FB9F59F67B34Q47796770-97EB3B96-4199-4217-8201-50700EAA3E0BQ50985091-6F214250-7ACC-41A8-93A6-132011EF0D23Q51152435-337214D8-359B-43FF-B542-AE6E585E1889
P2860
A phase II evaluation of AMG 102 (rilotumumab) in the treatment of persistent or recurrent epithelial ovarian, fallopian tube or primary peritoneal carcinoma: a Gynecologic Oncology Group study.
description
2013 nî lūn-bûn
@nan
2013年の論文
@ja
2013年論文
@yue
2013年論文
@zh-hant
2013年論文
@zh-hk
2013年論文
@zh-mo
2013年論文
@zh-tw
2013年论文
@wuu
2013年论文
@zh
2013年论文
@zh-cn
name
A phase II evaluation of AMG 1 ...... ecologic Oncology Group study.
@ast
A phase II evaluation of AMG 1 ...... ecologic Oncology Group study.
@en
type
label
A phase II evaluation of AMG 1 ...... ecologic Oncology Group study.
@ast
A phase II evaluation of AMG 1 ...... ecologic Oncology Group study.
@en
prefLabel
A phase II evaluation of AMG 1 ...... ecologic Oncology Group study.
@ast
A phase II evaluation of AMG 1 ...... ecologic Oncology Group study.
@en
P2093
P2860
P1433
P1476
A phase II evaluation of AMG 1 ...... ecologic Oncology Group study.
@en
P2093
James Hoffman
Lainie P Martin
Lisa M Landrum
Matthew Powell
Michael J Goodheart
Michael Sill
Paul DiSilvestro
Russell J Schilder
Stephanie L Gaillard
P2860
P304
P356
10.1016/J.YGYNO.2013.12.018
P407
P577
2013-12-18T00:00:00Z